INCATE - Incubator for Antibacterial Therapies in Europe
Multi-resistant bacteria are spreading worldwide. New antibiotics and strategies against deadly infectious diseases are urgently needed. The INCATE consortium (Incubator for Antibacterial Therapies in Europe) aims to boost the development of new drugs. To this end, partners from the academic, industrial and public sectors are working together. In addition to the DZIF, the academic founding members include the research association Leibniz-HKI in Germany, the Swiss National Centre of Competence in Research AntiResist and the University of Basel. Since November 2023, the French Microbiology Technology Research BIOASTER has also been involved as an academic partner.
Together with supporters from industry and with other organisations, INCATE wants to ensure that the pipeline of new antibiotics is filled and strengthened. Expert advice, building of a community supporting ventures´ development and targeted funding are the three tools with which INCATE aims to achieve this goal.